Open Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes

[Hoopoe]

In fibromyalgia, chronic fatigue syndrome, multiple sclerosis and healthy controls. 120 participants in total.

https://clinicaltrials.gov/ct2/show...&cond=Chronic+Fatigue+Syndrome&draw=2&rank=11

The start date is listed as September 30, 2019.

 

[Andy]

University of Alabama, so presumably part of Younger's lab?

Selection criteria for CFS is Fukuda.

 

[rvallee]

Selection criteria for CFS is Fukuda.

 

[shak8]

It's not Jerrud Younger. It's
Jonathan McConathy, MD, PhD
Contact: April Riddle, BSRT

Their contact details are on the Clinical trials document.

You could tell them what's wrong with Fukuda.

 

[Londinium]

If there is a concern about selection criteria, might I suggest trying to coordinate one response, politely explaining why patients have concerns about Fukuda.

 

[Medfeb]

NIH's and CDC's current position is that we do not know enough to designate a specific definition and that any definition - including Fukuda - is acceptable. That means that not even PEM is mandatory. (edited to add - "not mandatory" according to NIH's and CDC's position)

Food for thought... it might be better to make the case to NIH and CDC rather than individual researchers. At the very least, we need NIH to sponsor a meeting of researchers and clinicians to reach consensus on the criteria and the methods used to assess those criteria.

 

[Cinders66]

This apart from CFS criteria looks quite good. If the researcher is new perhaps he’s not up to date with the moving away from Fukuda? I wonder if this is how research grows, maybe he heard of youngers research through university networking and has sparked his interest ?

 

[Colleen Steckel]

A unified front about what criteria is best for research into ME should already exist.

I think we can all agree that Fukuda (just like Oxford) isn't appropriate for anything that could be seen as an "ME" study.

It's labeled a "CFS" study and uses Fukuda. What that means is another study would need to be done in order to see if it applies to PwME. Can't we approach this as a waste of precious research dollars?

 

[wigglethemouse]

Jarred Younger has a very similar project to this funded by ME Research UK using a different zirconium-89 radioisoptope with 15 women participants with ME/CFS and 10 controls.
http://www.meresearch.org.uk/our-research/ongoing-studies/immune-cell-infiltration/

 

[wigglethemouse]

Jarred Younger has a very similar project to this funded by ME Research UK using a different zirconium-89 radioisoptope with 15 women participants with ME/CFS and 10 controls.
http://www.meresearch.org.uk/our-research/ongoing-studies/immune-cell-infiltration/

Duh, just realised the title of this thread shows [Zr-89]. So I bet it is the same study, with the ME/CFS analysis funded by ME Research UK.

 

[forestglip]

Study completion has been changed from 2025 to 2028.

ClinicalTrials.gov

 

[forestglip]

University of Alabama, so presumably part of Younger's lab?

Selection criteria for CFS is Fukuda.

It seems like he might use a modified Fukuda in his studies which requires PEM.

This 2019 study from his lab says "participants with ME/CFS had to meet the following inclusion criteria: (i) age between 18–55 years; (ii) met Fukuda case definition criteria for ME/CFS (Fukuda et al., 1994), without the Reeves et al. (2005) modifications but with additional criteria proposed by Jason et al. (2010);".

And that Jason et al. paper gives an ME/CFS criteria whose second requirement is:

"Post-exertional malaise and/ or post-exertional fatigue. With activity (it need not be strenuous and may include walking up a flight of stairs,
using a computer, or reading a book), there must be a loss of physical or mental stamina, rapid/sudden muscle or cognitive fatigability, post-
exertional malaise and/or fatigue and a tendency for other associated symptoms within the patient’s cluster of symptoms to worsen. The
recovery is slow, often taking 2-24 hours or longer."